Dario Aiello

Dario Aiello


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Tumori Journal
Verified
Journal Article
Closed access
DADario Aiello
Dario Aiello
RMRosario Mazzola
Rosario Mazzola
Fabiana GregucciFabiana Gregucci
Fabiana Gregucci
FRFrancesco Ricchetti
Francesco Ricchetti
NLNiccolò Giaj Levra
Niccolò Giaj Levra
Filippo AlongiFilippo Alongi
Filippo Alongi
Purpose: Intramedullary spinal cord metastases (ISCM) are considered rare but their incidence is rising. Most ISCM cases are recognized to occur in patients with stage IV lung cancer or breast cancer (BC). Methods: We report a rare case of cervical BC-ISCM in 60-year-old woman, documented by magnetic resonance imaging and positron emission tomography–computed tomography and treated with volumetric modulated arc therapy with daily image-guided radiation therapy (VMAT/IGRT). Results: An unexpected clinical and radiologic complete response in absence of neurologic side effects was recorded 4 months after VMAT/IGRT. Conclusions: The present case report shows the feasibility of advanced RT and its optimal response in a case of ISCM from BC. Despite the short follow-up, in comparison with available literature data concerning the management of BC-ISCM, we found an early complete response, in contrast with other reported experiences.

27 September 2024 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
MVMaria La Vecchia
Maria La Vecchia
MFManuela Federico
Manuela Federico
DADario Aiello
Dario Aiello
VZValentina Zagardo
Valentina Zagardo
AMAntonella Mazzonello
Antonella Mazzonello
IFIvan Fazio
Ivan Fazio
Background: This multicentric, retrospective study investigated the use of stereotactic body radiotherapy (SBRT) in patients (pts) with metastatic renal cell carcinoma (mRCC) who experienced oligoprogression during a combination therapy with an immune checkpoint inhibitor (ICI) and a tyrosine–kinase inhibitor (TKI). Methods: We retrospectively evaluated 34 pts affected by oligoprogressive RCC treated with an ICI–TKI combination between January 2020 and December 2023. SBRT was delivered to each site of oligoprogressive metastatic disease. After SBRT, pts were given follow-up clinical evaluations. 6–12–18-month local control (LC) rates and median next-line treatment-free survival (NEST-FS) were the primary endpoints. The secondary endpoints were overall response rate (ORR), clinical benefits and safety. Results: After a median follow-up of 24 months, 6–12–18-month LC rates were 100%, 71% and 43%, respectively, and the median NEST-FS was 20 months. ORR was 90%, while clinical benefit was 100%. No > G2 adverse events related to SBRT were recorded. Conclusions: In our study, SBRT for oligoprogressive mRCC turned out to be a safe and useful treatment which was able to preserve current treatment. Further prospective studies are necessary to explore the effects of the ICIs–TKIs combination and SBRT upon oligoprogressive sites in mRCC.


1 September 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
RMRosario Mazzola
Rosario Mazzola
DADario Aiello
Dario Aiello
FRFrancesco Ricchetti
Francesco Ricchetti
Filippo AlongiFilippo Alongi
Filippo Alongi